Priscilla Y Hsue1, Heather J Ribaudo2, Steven G Deeks1, Tanvir Bell3, Paul M Ridker4, Carl Fichtenbaum5, Eric S Daar6, Diane Havlir1, Eunice Yeh2, Ahmed Tawakol7, Michael Lederman8, Judith S Currier6, James H Stein9. 1. Department of Medicine, University of California, San Francisco School of Medicine, Boston, Massachusetts. 2. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. McGovern Medical School, University of Texas Health Science Center at Houston, Boston, Massachusetts. 4. Cardiology Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 5. University of Cincinnati College of Medicine, Ohio. 6. David Geffen School of Medicine, University of California, Los Angeles, Boston. 7. Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston. 8. Case Western Reserve University School of Medicine, Cleveland, Ohio. 9. University of Wisconsin School of Medicine and Public Health, Madison.
Abstract
BACKGROUND: Chronic inflammation in treated HIV infection is associated with mortality and atherosclerotic cardiovascular disease (ASCVD). We evaluated the safety and potential efficacy of low-dose methotrexate (LDMTX) in treated HIV. METHODS: This was a phase 2 randomized, double-blind, multicenter trial in adults ≥40 years old with treated HIV, with CD4+ T-cell count ≥400 cells/μL and with/at increased risk for ASCVD. Participants received LDMTX (5-15 mg/week) or placebo (plus folic acid) for 24 weeks and were followed for an additional 12 weeks. Primary endpoints were safety and brachial artery flow-mediated dilation (FMD). RESULTS: The 176 participants (90% male) had a median (Q1, Q3) age of 54 (49, 59) years. LDMTX was associated with decreases in CD4+ T cells at week 24 and CD8+ T cells at weeks 8, 12, and 24. Eleven participants (12.8%) experienced safety events in the LDMTX group vs 5 (5.6%) in placebo (Δ = 7.2%, upper 1-sided 90% CI, 13.4%; Pnoninferiority = .037). Week 24 change in FMD was 0.47% with LDMTX and 0.09% with placebo (P = .55). No inflammatory markers changed differentially with LDMTX compared to placebo. CONCLUSIONS:Adults with HIV and increased ASCVD risk treated withLDMTX had more safety events than with placebo, but the prespecified noninferiority margin of 15% was not exceeded. LDMTX had no significant effect on endothelial function or inflammatory biomarkers but was associated with a significant decrease in CD8+ T cells. The balance of risks and potential benefits of LDMTX in this population will require additional investigation. CLINICAL TRIALS REGISTRATION: NCT01949116.
RCT Entities:
BACKGROUND:Chronic inflammation in treated HIV infection is associated with mortality and atherosclerotic cardiovascular disease (ASCVD). We evaluated the safety and potential efficacy of low-dose methotrexate (LDMTX) in treated HIV. METHODS: This was a phase 2 randomized, double-blind, multicenter trial in adults ≥40 years old with treated HIV, with CD4+ T-cell count ≥400 cells/μL and with/at increased risk for ASCVD. Participants received LDMTX (5-15 mg/week) or placebo (plus folic acid) for 24 weeks and were followed for an additional 12 weeks. Primary endpoints were safety and brachial artery flow-mediated dilation (FMD). RESULTS: The 176 participants (90% male) had a median (Q1, Q3) age of 54 (49, 59) years. LDMTX was associated with decreases in CD4+ T cells at week 24 and CD8+ T cells at weeks 8, 12, and 24. Eleven participants (12.8%) experienced safety events in the LDMTX group vs 5 (5.6%) in placebo (Δ = 7.2%, upper 1-sided 90% CI, 13.4%; Pnoninferiority = .037). Week 24 change in FMD was 0.47% with LDMTX and 0.09% with placebo (P = .55). No inflammatory markers changed differentially with LDMTX compared to placebo. CONCLUSIONS: Adults with HIV and increased ASCVD risk treated with LDMTX had more safety events than with placebo, but the prespecified noninferiority margin of 15% was not exceeded. LDMTX had no significant effect on endothelial function or inflammatory biomarkers but was associated with a significant decrease in CD8+ T cells. The balance of risks and potential benefits of LDMTX in this population will require additional investigation. CLINICAL TRIALS REGISTRATION: NCT01949116.
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: D Hürlimann; R Chenevard; F Ruschitzka; M Flepp; F Enseleit; M Béchir; R Kobza; J Muntwyler; B Ledergerber; T F Lüscher; G Noll; R Weber Journal: Heart Date: 2005-03-29 Impact factor: 5.994
Authors: James H Stein; Michelle A Merwood; Jennifer L Bellehumeur; Susan E Aeschlimann; Claudia E Korcarz; Gail L Underbakke; Maureen E Mays; James M Sosman Journal: Am Heart J Date: 2004-04 Impact factor: 4.749
Authors: Steven G Deeks; Christina M R Kitchen; Lea Liu; Hua Guo; Ron Gascon; Amy B Narváez; Peter Hunt; Jeffrey N Martin; James O Kahn; Jay Levy; Michael S McGrath; Frederick M Hecht Journal: Blood Date: 2004-04-29 Impact factor: 22.113
Authors: Noyan Gokce; John F Keaney; Liza M Hunter; Michael T Watkins; Zoran S Nedeljkovic; James O Menzoian; Joseph A Vita Journal: J Am Coll Cardiol Date: 2003-05-21 Impact factor: 24.094
Authors: James H Stein; Eunice Yeh; Joanne M Weber; Claudia Korcarz; Paul M Ridker; Ahmed Tawakol; Priscilla Y Hsue; Judith S Currier; Heather Ribaudo; Carol K C Mitchell Journal: Arterioscler Thromb Vasc Biol Date: 2018-12 Impact factor: 8.311
Authors: James H Stein; Noah Kime; Claudia E Korcarz; Heather Ribaudo; Judith S Currier; Joseph C Delaney Journal: Arterioscler Thromb Vasc Biol Date: 2020-12-17 Impact factor: 8.311
Authors: Allison G Hays; Michael Schär; Patricia Barditch-Crovo; Shashwatee Bagchi; Gabriele Bonanno; Joseph Meyer; Yohannes Afework; Valerie Streeb; Samuel Stradley; Shannon Kelly; Nicole M Anders; Joseph B Margolick; Shenghan Lai; Gary Gerstenblith; Robert G Weiss Journal: AIDS Date: 2021-06-01 Impact factor: 4.632
Authors: Kristine M Erlandson; Melissa P Wilson; Samantha MaWhinney; Eric Rapaport; Jay Liu; Cara C Wilson; Jeremy T Rahkola; Edward N Janoff; Todd T Brown; Thomas B Campbell; Catherine M Jankowski Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226